Preparation of Oral Poster Presentation

Preparation of Oral Poster Presentation

Preparation of Oral Presentation

  • The official language for oral presentation is in English. The oral presentation, slide, and handouts should be written in English.
  • Software: Microsoft PowerPoint or PowerPoint compatible version of Keynote only.
  • Preferred fonts: Arial, Verdana, Helvetica or Calibri
  • Slide presentation aspect ratio 4:3
  • Use legible type size.
    Titles: At least 40 points.
    Bulleted text or body copy: 28 points minimum.

You will have 10 minutes to make your presentation and 2 minutes to questions and answers from the audience. More details on the next communication.

Location:           at the meeting room, 2nd floor, The Empress Convention Center

Date and time:  14 May 2016, at 16:00 17:00 hr.

Note: Please download your slide at boardroom 3(on the 1st floor), before 15.00 hr. on 14 May 2016.

 

Preparation of Poster Presentation

  • The poster must be written in English and must cover the same material as the abstract submitted. Title and author(s) must also be included on the poster.
  • Include your POSTER NUMBER once you receive it in the top left corner in your poster materials. The number should be large enough for people to quickly identify your poster as they are walking down the aisles.
  • Prepare all illustrations neatly and legibly beforehand in a size sufficient to be read at a distance of 8 feet (240 cm). Letters should be at least 6 mm in height for the text and 10 mm for the section headings.
  • The board will be used VERTICALLY.  Dimensions of the poster board are 237 cm high x 95 cm wide. These are the maximum dimensions to follow when creating your poster, but you should make your poster smaller. Recommended size is 120 cm high x 95 cm wide.
  • Please bring your own supplies to mount posters: double sided tape, masking tape, adhesive putty, etc.

Location:            2nd floor, The Empress Convention Center

Set up time:       13 May 2016, 08.00 hr. onward

Recommended Poster Printing Contractor

                   Triple M Infinity Co., Ltd.

Contact:        Ms.Tunchaya Kamai

Address:       200/94 Moo.5, Tumbol Fahum , Amphur Muang Chiang Mai 50000, Thailand

Tel:               +66 (0) 86 191 9265, +66 (0) 81 672 6077

Fax:              +66 (0) 53 266 600

E-mail:          triple-m2009@hotmail.com

 

APLCC 2016 Oral Presentation

ID Title Topic Area Country Present Type Meeting Room Author Time
ABS047 Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer Medical oncology China Oral Chiang Mai 1-2 Dr. Hong-Fei Gao 16.00 16.12 hr.
ABS068 First-line afatinib versus gefitinib in patients with epidermal growth factor receptor mutation positive non-small cell lung cancer (LUX-Lung 7): efficacy and safety in Asian patients Medical oncology Australia Oral Chiang Mai 1-2 Dr. Ken O’Byrne 16.12 16.24 hr.
ABS134 Impact of dose adjustment on afatinib safety and efficacy in epidermal growth factor receptor mutation-positive non-small cell lung cancer: post-hoc analyses of LUX-Lung 3/LUX-Lung 6 Medical oncology China Oral Chiang Mai 1-2 Prof. Yi-Long Wu 16.24 16.36 hr.
ABS142 Overall survival with afatinib vs chemotherapy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: LUX-Lung 3 and 6 race subgroup analyses Medical oncology China Oral Chiang Mai 1-2 Prof. Yi-Long Wu 16.36 16.48 hr.
ABS168 Phase III trial of second-line afatinib versus erlotinib in patients with squamous cell carcinoma of the lung (LUX-Lung 8): tumor genetic analysis and survival outcomes Medical oncology South Korea Oral Chiang Mai 1-2 Dr. Keunchil Park 16.48 17.00 hr.
ABS132 An alternative bronchial division procedure in right upper lobectomy indicates better operative outcomes for lung cancer patients Surgery China Oral Chiang Mai 4-5 Dr. Hao-ran Zhai 16.00 16.12 hr.
ABS140 Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer Surgery China Oral Chiang Mai 4-5 Prof. Feng Mu 16.12 16.24 hr.
ABS128 Retrospective Analysis of 287 Consecutive Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomies at a Single Institution: A Bi-Phasic Learning Curve Surgery United States Oral Chiang Mai 4-5 Assoc. Prof Eric Toloza 16.24 16.36 hr.
ABS098 Stromal PD-L1+ Tregs and PD-1+ CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy Immunology/Immunotherapy China Oral Chiang Mai 4-5 Dr. Sipei Wu 16.36 16.48 hr.
ABS024 Prophylactic cranial irradiation could not show the overall survival benefits of patients with extensive disease small cell lung cancer: Results of Radiotherapy Japan Oral Chiang Mai 3 Dr. Takashi Seto 16.00 16.12 hr.
ABS046 Expression of Fibroblast Growth Factor Receptor 1 might not be a prognostic biomarker in patients with squamous cell lung cancer Biology China Oral Chiang Mai 3 Dr. Qi Zhang 16.12 16.24 hr.
ABS092 Is there pattern and risk factors of lymph node metastases in cN0 peripheral non small cell lung cancer? Pulmonology China Oral Chiang Mai 3 Dr. Jun-tao Lin 16.24 16.36 hr.
ABS145 Different pathological predominant subtypes of primary pulmonary invasive adenocarcinomas pictured genetic mutation preferences Pathology China Oral Chiang Mai 3 Dr. Hao-ran Zhai 16.36 16.48 hr.

Poster Presentation on 14 May 2016

ID Title Topic Area Country Author Poster No.
ABS002 Hope For People Living With Advanced Lung Cancer Nursing & supportive care India Mr. Aditya Manna PA30
ABS017 Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer Medical oncology Japan Dr. Hisao Imai PA10
ABS027 Prognostic Impact of Tumor Volume in Patients with Clinical Stage IA Non-Small Cell Lung Cancer Imaging / staging Japan Dr. Tomoyoshi Takenaka PA09
ABS029 Clinical characteristics of pulmonary sarcomatoid carcinoma Epidemiology South Korea Prof. Sung Yong Lee PA06
ABS030 Protective effect of Erdosteine on Cisplatin-induced nephrotoxicity Medical oncology South Korea Assoc. Prof Chang Youl Lee PA11
ABS036 Clinical modes of EGFR tyrosine kinase inhibitor failure and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR in advanced NSCLC Medical oncology China Dr.  Cheng-Liang Yang PA12
ABS049 Interim results of a feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small cell lung cancer Medical oncology Japan Assoc. Prof Hisashi Saji PA13
ABS051 The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma Medical oncology China Mrs. Qiu-Yi Zhang PA14
ABS053 Is pharmacokinetics of carnitine a prediction factor of fatigue in thoracic cancer patients treated with cisplatin-containing chemotherapy? Medical oncology Japan Prof. TATSUHIKO KASHII PA15
ABS054 The Comparison of Therapeutic Efficacy for Available EGFR-TKIs in Advanced EGFR-Positive Non–Small Cell Lung Cancer: A Network Meta-Analysis Based on Head-To-Head Trials Medical oncology China Dr. Yaxiong Zhang PA16
ABS055 Prognostic impact of incomplete interlober fissure in early stage lung cancer patients underwent thoracoscopic lobectomy. Surgery South Korea Prof. DEOG GON CHO PA36
ABS056 Stereotactic Ablative Radiotherapy for Early-Stage, Including T3, Non-Small Cell Lung Cancer Radiotherapy South Korea Assoc. Prof Seung-Gu Yeo PA33
ABS058 Comparison efficacy of preoperative chemotherapy and surgery with surgery alone in patients with stage IIIA Non-small-cell lung cancer Medical oncology Uzbekistan Dr. Farrukh Djuraev PA17
ABS060 Molecular Epidemiological Study of EML4-ALK Fusion Gene using Immunohistochemistry (IHC) as a Cost Effective Alternative to FISH for Indian Patients with Adenocarcinoma Lung Biology India Dr. Anurag Mehta PA01
ABS062 Study of epidemiological factors, molecular profile and pattern of metastasis of adenocarcinoma lung in Indian female patients Medical oncology India Dr. CHATURBHUJ AGRAWAL PA18
ABS069 Maximize benefit of EGFR TKIs treatment by BIM polymorphism/expression testing in EGFR positive NSCLC Medical oncology Thailand Dr. Chanchai charonpongsuntorn PA19
ABS070 Sequential EGFR-TKI strategy to overcome acquired resistance to afatinib: novel secondary mutations L792F and C797S in addition to T790M Medical oncology Japan Dr. Yoshihisa Kobayashi PA20
ABS072 UTILIZATION OF THE 7TH EDITION OF THE TUMOR NODE METASTASIS (TNM) SYSTEM AND STAGE FOR LUNG CANCER IN THE MONGOLIA Radiology / screening Mongolia Dr. tsevelmaa dorj PA32
ABS074 Pembrolizumab Versus Platinum-Based Chemotherapy for PD-L1+ NSCLC in a Phase 3, Randomized, Open-Label Study: KEYNOTE-042 Medical oncology Hong Kong Prof. Tony Mok PA21
ABS075 IL-6 promotes radiation-induced macrophage infiltration to lung tumors via up-regulation of CCL2 and CCL5 Radiotherapy United States Prof. Yuhchyau Chen PA34
ABS076 ALK rearrangement testing by Immunohistochemistry in NSCLC patients: results from an Indian Centre Epidemiology India Dr. Satheesh CT PA07
ABS081 Postprogression Continuation versus Discontinuation of Tyrosine Kinase Inhibitor (TKI) in Non-Small Cell Lung Cancer with Isolated Progression and Common EGFR Mutation Medical oncology China Dr. Lei Deng PA22
ABS082 The role of adjuvant chemotherapy in stage II/III NSCLC patients and the predict value of BIM polymorphism Medical oncology China Ms. feiyu niu PA23
ABS084 Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations Medical oncology Japan Dr. Yoko Naoki PA25
ABS085 Mixed responses to systemic therapy in NSCLC patients evaluated by PET/CT indicate clinical significance for predicting survival and genetic intertumoral heterogeneity Medical oncology China Dr. Zhong-Yi Dong PA26
ABS086 Epidermal growth factor receptor mutant-specific inhibitor BI 1482694 (HM61713) in T790M-positive non-small cell lung cancer: efficacy, safety and pharmacokinetics at the recommended Phase II dose Medical oncology South Korea Prof. Keunchil Park PA27
ABS087 The Benefit of Cryosurgery on Multiple Nodules in Lung Malignancy (Serial Case report) Surgery Indonesia Dr. DARMAWAN ISMAIL PA37
ABS088 Rebiopsy of histological samples to confirm T790M/programmed death ligand-1 status in pretreated non-small cell lung cancer Medical oncology Japan Dr. Akito Hata PA28
ABS091 MET exon 14 mutation may not be a predict  biomarker in Chinese patients Medical oncology China Dr. Lan-Ying Gou PA29
ABS094 Salvage radiotherapy for locoregionally recurrent non-small cell lung cancer after resection Radiotherapy South Korea Dr. JAE-SUNG KIM PA35
ABS106 Clinical characteristics and survival outcome among non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement Epidemiology Malaysia Ms. Yvonne Lee PA08
ABS129 Peri-Operative Factors that Predict Prolonged Air Leaks after Robotic-Assisted Thoracoscopic Pulmonary Lobectomy Surgery United States Assoc. Prof Eric Toloza PA38
ABS139 Cryotherapy for metastatic central type lung cancer: A retrospective analysis Surgery China Alan Montanaro PA39
ABS144 Whole-exome sequencing for lung adenocarcinoma patients with heterogeneous progression patterns Biology China Dr. Ee Ke PA02
ABS153 SENSITIVE DETECTION OF RARE CANCER CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH LUNG CANCER BY PREPROGRP-SPECIFIC RT-PCR and its correlation with clinicopathological data and survival. Combined modality Egypt assistant consultant fatma abou el-kasem PA03
ABS158 ALTERNATE METHOD TO PROVIDE PALLIATIVE CARE WHERE THERE ARE SHORT CAREGIVERS Nursing & supportive care India Mr. Aditya Manna PA31
ABS161 Advanced Non Small Cell Lung Cancer In National Cancer Institute Egypt-A Discreptive Analysis Epidemiology Egypt Dr. hala  shokralla makar PA05
ABS165 Non-small cell lung cancer in patients 45 years old or less; clinicopathologic criteria and prognostic factors Combined modality Egypt Dr. M. Rahouma PA04
ABS171 Pulmonary Resection in Elderly Patients with Non-Small Cell Lung Cancer; Prognostic Factors of Long-Term Mortality Surgery Thailand Dr. Sophon Siwachat PA40

Poster Presentation on 15 May 2016

ID Title Topic Area Country Author Poster No.
ABS038 Role of pictorial warning on cigarette packets in tobacco cessation- A questionnaire survey among cigarette smokers in India. Smoking cessation India Mr. Clement Joy Kingsly Francis PB35
ABS089 Utility of FDG-PET/CT imaging in assessing mucinous non-small-cell lung cancer Pulmonology China Dr. Wei Li PB29
ABS093 Molecular Mechanism of Transformation From Adenocarcinoma to small-cell lung cancer after EGFR-TKI Medical oncology China Mr. Jie-fei Han PB07
ABS095 Impact of T790M genotype on post-progression survival of patients with exon 19 deletion versus those with L858R mutation Medical oncology China Ms. Ee Ke PB08
ABS097 The Cellsearch Veridex technology improves diagnostic accuracy of leptomeningeal metastases in lung cancer Medical oncology China Dr. yang-si li PB09
ABS099 Quantification of EGFR Mutations in Plasma Circulating DNA by Droplet Digital PCR from Patients with advanced NSCLC Medical oncology China Mrs. Qiu-Yi Zhang PB10
ABS100 Clinical efficacy and Safety profile of Crizotinib in ALK positive NSCL- a study from Bangalore. Medical oncology India Dr. Satheesh CT PB11
ABS102 Treatment Response and Survival of Advance Lung Adenocarcinoma Patients in a Real-World Setting (TREASURE) Medical oncology Malaysia Dr. Chai Chee Shee PB12
ABS105 An exploratory comparative analysis of 5-year survival or 9.5-month survival of non-small cell lung cancer patients treated with EGFR-TKIs Medical oncology China Ms. Jin Kang PB13
ABS107 Alterations of de novo Gas6/AXL in advanced lung adenocarcinoma Medical oncology China Dr. hui-wen sun PB14
ABS108 Gefitinib versus Erlotinib as First-line Treatment in Patients with Epidermal Growth Factor Receptor Mutant Advanced Lung Adenocarcinoma Medical oncology Malaysia Dr. Chai Chee Shee PB15
ABS109 Second-Line Treatments after Disease Progression in Malaysian Patients with Advanced Lung Adenocarcinoma Medical oncology Malaysia Dr. Chai Chee Shee PB16
ABS110 Second-line Treatment Significantly Affects the Overall Survival of Advanced Lung Adenocarcinoma Patients upon Disease Progression with First-line Treatment. Medical oncology Malaysia Dr. Chai Chee Shee PB17
ABS112 Different kinds of co-alterations in ALK-rearranged non-small-cell lung cancer Medical oncology China Dr. Rui-lian Chen PB18
ABS113 Favorable Clinical outcomes to pemetrexed-based chemotherapy in ROS1-rearranged non-small cell lung cancer (NSCLC) patients Medical oncology South Korea Dr. Kwai Han Yoo PB19
ABS115 Clinicopathological Profile, Epidermal Growth Factor Receptor Mutation and One-Year Survival of Non-Small Cell Lung Cancer in Dharmais National Cancer Hospital-Indonesia Epidemiology Indonesia Dr. Edel Herbitya PB04
ABS116 Clinical Characteristic and Overall Survival Outcomes of Non-Small Cell Lung Cancer in Young Patients at “Dharmais” National Cancer Hospital-Indonesia Epidemiology Indonesia Dr. Leovinna Widjaja PB05
ABS117 An analysis of epidemiology,treatment,recurrence patterns and outcome in patients of advanced stage inoperable lung cancer . Radiotherapy India Dr. Divyesh kumar PB31
ABS118 To study the epidemiological profile and clinical outcome of Advanced non small cell lung carcinoma patients who harbor Anaplastic lymphoma kinase gene rearrangement Medical oncology India Dr. rajeev saini PB20
ABS121 A tertiary care hospital based retrospective study evaluating epidemiology of lung cancers in western India. Epidemiology India Dr. SAURABH SAMDARIYA PB06
ABS135 Afatinib versus chemotherapy for epidermal growth factor receptor mutation-positive non-small cell lung cancer patients aged ≥65 years: subgroup analyses of LUX-Lung 3 and LUX-Lung 6 Medical oncology China Prof. Yi-Long Wu PB21
ABS141 Identification of an Optimal Shrinkage Threshold in Response Evaluation for Non-Small Cell Lung Cancer Patients Receiving Combinational Chemotherapy and Targeted Therapy Medical oncology China Dr. zhonghan zhang PB22
ABS146 The Cost-Effectiveness Analysis of Second-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Thai Patients with Advanced Non-Small Cell Lung Cancer Medical oncology Thailand Ms. Tanavadee Siritanadeepun PB23
ABS148 ALK Positive lung cancer: Clinical profile, practice and outcomes in a developing country Medical oncology India Dr. Anant Ramaswamy PB24
ABS149 Preclinical evidence of BPI-7711 activity in EGFR-mutant non-small cell lung cancer (NSCLC) in orthotopically implanted human tumor xenografts in the lung and brain Biology United States Dr. Victoria Wilde PB01
ABS150 Phase Ib trial of afatinib and BI 836845 in patients with advanced non-small cell lung cancer Medical oncology Thailand Prof. Daniel Shao Weng Tan PB25
ABS151 Global fight against cancer: Implementation of lung Stereotactic Body Radiotherapy program in developing countries through International Collaboration Radiotherapy Jordan Dr. JAMAL KHADER PB32
ABS152 Jordan lung CT screening program as a model in a developing country Radiology / screening Jordan Dr. JAMAL KHADER PB30
ABS155 Elective Brain Irradiation and Relapses in Limited Disease Inoperable Non-Small Cell Lung Cancer Patients without Progressive Disease after Combined Chemo-Radiotherapy Radiotherapy Thailand Dr. Krit Pongpirul PB33
ABS157 Phase IV study of second-line afatinib in patients with locally advanced/metastatic non-small cell lung cancer harboring common epidermal growth factor receptor mutations (Del19 and/or L858R) Medical oncology Thailand Prof. Sumitra Thongprasert PB26
ABS159 The Role Of Volunteers In Quality Palliative Care Delivery Nursing & supportive care India Mr. Aditya Manna PB28
ABS160 Retrospective analysis of lung tumour motion in Cone Beam Computed Tomography (CBCT) for radical lung patients receiving radiotherapy Radiotherapy Australia Mrs. Siobhan Whiting PB34
ABS162 The clinicopathological and prognostic significance of CD44 and ALDH1 expression in adenocarcinoma of lung Biology South Korea Prof. Dae Sung Hyun PB02
ABS170 Study to analyse and compare the quality of life in patients of advanced stage lung cancer undergoing two different modalities of treatment. Combined modality India Dr. Divyesh kumar PB03
ABS173 Budget Impact Analysis (BIA) to assess the affordability of Crizotinib treatment for non-small cell lung cancers (NSCLC) with Anaplastic Lymphoma Kinase rearrangement (ALK+) Medical oncology Malaysia Ms. Yvonne Lee PB27